Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone talked with Proactive's Stephen Gunnion about the company’s latest trading update and growth outlook for 2025. Gouldstone highlighted that Oncimmune experienced a strong 2024, with revenues on track to hit £3 million. He attributed this to new commercial strategies and the company’s 81% repeat business rate. He noted that projects are now starting on time, with sample availability improving. Looking ahead, Gouldstone said that Oncimmune expects an even stronger second half of 2025, with an expanding pipeline and a maturing sales team generating new opportunities. He acknowledged that industry-wide delays in big pharma budgets had slowed conversions but expressed optimism that spending would rebound. The company is currently negotiating with 11 new customers while also securing follow-on business from existing clients. When asked about “transformative opportunities”, Gouldstone mentioned three potential deals that could be significant in scale, though he could not yet disclose details. “I think it could really be the year that the Oncimmune profiling technology truly comes of age,” said Gouldstone. Watch the full interview to hear more about Oncimmune’s strategy for 2025. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future updates from Proactive. #Oncimmune #Biotech #CancerDetection #MedicalResearch #HealthcareInnovation #Pharma #Investing #StockMarket #CEOInterview #Oncology #ProactiveInvestors